Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
neosh101
- Development stage
- Phase 2
- Lead developer
- LEO Pharma
- Modality
- Peptides
- Administration
- Topical
01
Overview
NEOSH101 is a synthetic peptide drug developed as a topical treatment for androgenetic alopecia (male pattern hair loss). It was originally developed by Neosil and later acquired by Peplin, which itself was subsequently acquired by LEO Pharma. The drug was designed to promote hair growth in patients with androgenetic alopecia, but its precise mechanism of action remains undefined. Clinical trials reached Phase 2, where NEOSH101 demonstrated significant increases in hair growth among men with pattern hair loss. However, development for this indication has been discontinued[1][2][3].
- Other names
- NEOSH 101NEOSH101NEOSH-101
02
Targets
26S proteasome
Beyond the preview
Go deeper on neosh101.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on neosh101.